The value of animal models for drug development in multiple sclerosis

Author： Friese Manuel A.   Montalban Xavier   Willcox Nick   Bell John I.   Martin Roland   Fugger Lars  

Publisher： Oxford University Press

ISSN： 1460-2156

Source： Brain, Vol.129, Iss.8, 2006-08, pp. : 1940-1952

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of biomarkers in multiple sclerosis

By Bielekova Bibiana   Martin Roland  

Brain, Vol. 127, Iss. 7, 2004-07 ,pp. : 1463-1478

Oxford University Press

Access to resources Recommend Favorite

Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research

By Gold Ralf   Linington Christopher   Lassmann Hans  

Brain, Vol. 129, Iss. 8, 2006-08 ,pp. : 1953-1971

Oxford University Press

Access to resources Recommend Favorite

Pharmacological and drug-free interventions for fatigue in multiple sclerosis

By Penner Iris-Katharina  

Neurodegenerative Disease Management, Vol. 3, Iss. 1, 2013-02 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite

An examination of four models predicting fatigue in multiple sclerosis

By Strober Lauren B.   Arnett Peter A.  

Archives of Clinical Neuropsychology, Vol. 20, Iss. 5, 2005-07 ,pp. : 631-646

Oxford University Press

Access to resources Recommend Favorite

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

By Giovannoni G.  

Brain, Vol. 126, Iss. 10, 2003-10 ,pp. : 2191-2202

Oxford University Press

Access to resources Recommend Favorite